Abstract
Background/Aim: Dietary interventions like time-restricted feeding (TRF) show promising anti-cancer properties. We examined whether therapeutic TRF alone or combined with immunotherapy would diminish renal tumor growth in mice of varying body weights. Materials and Methods: Young (7 week) chow-fed or older (27 week) high-fat diet (HFD)-fed BALB/c mice were orthotopically injected with renal tumor cells expressing luciferase. After tumor establishment, mice were randomized to ad libitum feeding or TRF +/− anti-CTLA-4. Body composition, tumor viability and growth, and immune responses were quantified. Results: TRF alone reduced renal tumor bioluminescence in older HFD-fed, but not young chow-fed mice. In the latter, TRF mitigated tumor-induced loss of lean- and fat-mass. However, TRF did not alter excised renal tumor weights or intratumoral immune responses and failed to improve anti-CTLA-4 outcomes in any mice. Conclusion: Therapeutic TRF exhibits modest anti-cancer properties but fails to improve anti-CTLA-4 immune checkpoint blockade in murine renal cancer.
Footnotes
Authors' Contributions
WJT, CP, and LN participated in the conception and design of the work. WJT, RO, JTG and LN performed experiments, data acquisition, and analysis. WJT, RO, JTG, CP, and LN participated in data interpretation, manuscript writing and revision, and approval of the final manuscript for submission and publishing. All Authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Conflicts of Interest
The Authors have declared that no conflicts of interest exist in relation to this study.
Funding
Research reported in this publication was supported by a University of Alabama at Birmingham Nutrition Obesity Research Center (NORC) Pilot and Feasibility Grant Program and NCI award #T32CA183926 to WJT, NCI award #T32CA047888 to RMO, NIH award #T32GM008111 to JTG, and NIH award #R21CA223126 to LAN.
- Received August 6, 2020.
- Revision received August 24, 2020.
- Accepted August 26, 2020.
- Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.











